Merand Pharmaceuticals, Inc

Hemo Sonics LLC is a medical technology company based in Charlottesville, VA. They specialize in developing and manufacturing innovative products for whole blood hemostasis testing, including the Quantra Hemostasis Analyzer and various cartridges and kits. Their technology has been FDA approved for viscoelastic testing in a range of medical indications, such as cardiac surgery, trauma, liver transplantation, and major orthopedic surgery. Hemo Sonics aims to improve bleeding management by reducing unnecessary blood product usage, complications associated with bleeding or transfusions, and the time between diagnostics and hemostatic intervention. With a focus on scientific research and clinical need, Hemo Sonics has published numerous publications and demonstrated the efficacy of their products in reducing blood product usage and improving patient outcomes. Their team of experienced professionals and management strive to provide healthcare providers with reliable and efficient solutions for viscoelastic testing, ultimately contributing to better bleeding management and patient care.Generated from the website

The Rilite Foundation, based in Charlottesville, VA, is dedicated to identifying and funding innovative research aimed at uncovering the causes and potential cures for lupus. With a focus on developing new treatments for systemic lupus erythematosus, the foundation addresses the significant challenges faced in drug development for this complex disease. Recognizing the urgent need for progress, Rilite Foundation seeks to overcome the obstacles posed by traditional drug development models, which have resulted in only one new treatment being approved for lupus in the past fifty years. By supporting novel research initiatives, the foundation aims to revitalize interest and investment in lupus treatment solutions. Generated from the website

PS Fertility in Charlottesville, VA, introduces a novel approach to male fertility testing with their innovative PS Detect diagnostic test. Departing from traditional methods that emphasize sperm count, shape, and motility, PS Fertility's new testing, PS Detect, delves deeper into sperm health, competency, and functionality. By shifting the focus from solely women to men, PS Fertility aims to redefine fertility testing by centering on the male's capacity to fertilize an egg. Co-founded by researchers Jeffrey Lysiak and Kodi Ravichandran from the University of Virginia School of Medicine, PS Fertility is at the forefront of pioneering fertility treatments based on cutting-edge insights into sperm and egg fusion. At the core of their testing lies the discovery of a crucial molecular marker, phosphatidylserine (PS), on sperm surfaces. This marker, indicative of sperm competency, plays a vital role in enabling the fusion of sperm with eggs for successful fertilization. PS Fertility's groundbreaking approach offers new avenues of hope for individuals navigating fertility challenges. Generated from the website content